Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun;103(6):e245-e248.
doi: 10.3324/haematol.2017.184358. Epub 2018 Feb 22.

Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias

Bernhard Gerber  1 , Martina Manzoni  2 , Valeria Spina  3 , Alessio Bruscaggin  3 , Marta Lionetti  2 , Sonia Fabris  4 , Marzia Barbieri  4 , Gabriella Ciceri  2 , Alessandra Pompa  4 , Gabriela Forestieri  3 , Erika Lerch  5 , Paolo Servida  5 , Francesco Bertoni  3 , Emanuele Zucca  5 , Michele Ghielmini  5 , Agostino Cortelezzi  2   4 , Franco Cavalli  3   5 , Georg Stussi  1 , Luca Baldini  2   4 , Davide Rossi  6   3 , Antonino Neri  7   4
Affiliations

Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias

Bernhard Gerber et al. Haematologica. 2018 Jun.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Overview of the mutations identified in the PC dyscrasia series. (A) Mutations detected in plasma cfDNA and confirmed in tumor gDNA are filled in red; mutations detected in tumor gDNA only are filled in blue. Each column represents one tumor sample and each row represents one gene. The fraction of tumors with mutations in each gene is plotted (right). The number and the type of mutations in a given tumor are plotted above the heat map. Patients positive for del(17p) are framed in black. (B) Bar graph of the allele frequencies in tumor gDNA of the variants that were discovered in plasma cfDNA (red bars) or missed in plasma cfDNA (blue bars). The dashed line tracks the 5% allelic frequency threshold.
See this image and copyright information in PMC

References

    1. Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046. - PubMed
    1. Lionetti M, Neri A. Utilizing next-generation sequencing in the management of multiple myeloma. Expert Rev Mol Diagn. 2017;17(7):653–663. - PubMed
    1. Diaz LA, Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32(6):579–586. - PMC - PubMed
    1. Oberle A, Brandt A, Voigtlaender M, et al. Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA. Haematologica. 2017;102(6):1105–1111. - PMC - PubMed
    1. Kis O, Kaedbey R, Chow S, et al. Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates. Nat Commun. 2017;8:15086. - PMC - PubMed

Publication types